Noventra Pharma Retatrutide (32mg Self-Mix – Triple GLP-1/GIP/Glucagon Agonist)

Retatrutide 32mg Self-Mix by Noventra Pharma is an investigational peptide formulation designed for research into metabolic regulation, obesity, and related endocrine pathways. Retatrutide functions as a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, thereby influencing appetite control, glucose metabolism, and energy expenditure through multiple physiological mechanisms. The self-mix format requires reconstitution prior to administration and is typically used where dosing can be titrated and monitored. Key Features: - 32mg retatrutide per vial - Triple agonist activity: GLP-1, GIP, and glucagon receptors - Studied for metabolic regulation, weight management, and glycaemic control - Requires reconstitution for controlled use - Supports appetite regulation and metabolic efficiency Suggested Use: Administration protocols vary depending on study design and are typically titrated over time. Use should be guided by qualified medical supervision. Storage: Store unreconstituted product in a cool, dry environment. Refrigerate after reconstitution at 2­8°C and use according to protocol. Protect from light and avoid repeated freeze-thaw cycles. Important Information: This is an investigational product and is not widely approved for general medical use. It should only be used within appropriate clinical or research settings under strict medical supervision. Potential risks may include gastrointestinal effects, hypoglycaemia, and other metabolic or endocrine-related complications.